BRINGING NEW POSSIBILITIES
TO SYSTEMIC AMYLOIDOSIS
Attralus is developing novel pan-amyloid removal (PAR) therapeutics that directly bind to and remove toxic amyloid, opening the potential to treat and reverse disease in all types of systemic amyloidosis.
All Disease Types
UNMET MEDICAL NEEDS
PATIENTS ARE IN NEED OF NEW TREATMENT OPTIONS
Systemic amyloidosis includes a diverse group of debilitating, progressive, and often fatal diseases, characterized by the accumulation of amyloid in vital organs.
- 80% of patients are undiagnosed.
- There are no therapies that remove amyloid and reverse disease.
- There are no therapies capable of treating all types and stages of systemic amyloidosis.
PAN-AMYLOID REMOVAL OFFERS A GAME-CHANGING APPROACH
Our pipeline will transform the treatment paradigm
Attralus is developing novel pan-amyloid removal (PAR) therapeutics that are designed to eliminate toxic, disease-causing amyloid in organs and tissues of patients with systemic amyloidosis.
Our proprietary technology has enabled us to develop novel biologics, as well as the world’s first amyloidosis-specific imaging agent that propel our strategy to identify and treat all stages and types of patients with this life-threatening disease. We aim to transform the treatment paradigm with disease-modifying amyloid removal — going beyond current treatments that slow progression, but do not remove amyloid from organs.
Our Team & Mission
Our mission at Attralus is to improve the lives of patients with systemic amyloidosis by developing transformational therapeutics that remove toxic amyloid. Our pan-amyloid removal (PAR) approach targets the underlying disease in all types of systemic amyloidosis, offering the potential to improve treatment outcomes for patients.